Ultrasound-Guided Versus Brainlab Navigation Sphenopalatine Ganglion Block in Functional Endoscopic Sinus Surgery
- Conditions
- UltrasoundBrainlab NavigationSphenopalatine Ganglion BlockFunctional Endoscopic Sinus Surgery
- Registration Number
- NCT06984913
- Lead Sponsor
- Tanta University
- Brief Summary
This study compares ultrasound-guided and Brainlab navigation sphenopalatine ganglion block (SPGB) in functional endoscopic sinus surgery (FESS).
- Detailed Description
Functional endoscopic sinus surgery (FESS) is the treatment modality of choice for the inflammatory disease of paranasal sinuses.
Sphenopalatine ganglion block (SPGB) is a regional analgesic technique that can be used as an alternative approach to reduce blood loss and improve the operative field during FESS without the need for hypotensive agents.
Ultrasound (US)-guided nerve block is a well-established technique in regional anesthesia and offers the advantage of real-time visualization of neural and vascular structures.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- Age from 18 to 65 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) physical status I-II.
- Patients undergoing functional endoscopic sinus surgery under general anesthesia.
- Patients having a history of severe renal, hepatic, respiratory, cardiac disease, or a neurological condition.
- Drug or alcohol abuse.
- Chronic pain requires major analgesics, sedatives, or corticosteroids.
- Pregnant and lactating women.
- Hypersensitivity to local anesthetic agents.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Surgical field condition 135 min post-procedure The Fromme-Boezaart scale (6-point scale) will be used to assess the endoscopic surgical field condition after GA induction, at the entrance of the endoscope, and after 15, 30, 45, 60, 75, 90, 105, 120, and 135 min.
0=No bleeding (cadaveric conditions).
1. Slight bleeding, no suctioning required.
2. Slight bleeding, occasional suctioning required.
3. Slight bleeding, frequent suctioning required; bleeding threatens the surgical field a few seconds after suction is removed.
4. Moderate bleeding, frequent suctioning required, and bleeding threatens the surgical field directly after suction is removed.
5. Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened, and surgery usually not possible.
- Secondary Outcome Measures
Name Time Method Intraoperative nitroglycerine consumption Intraoperatively Intraoperative requirements of nitroglycerine will be calculated.
Incidence of adverse events 24 hours postoperatively Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, or any other complication
Mean arterial pressure 135 min post-procedure Mean arterial pressure will be recorded after induction of general anesthesia, at entrance of endoscope, after 15, 30, 45, 60, 75, 90, 105, 120, and 135 min.
Intraoperative fentanyl consumption Intraoperatively To improve the conditions of the surgical field, hemodynamics will be managed (A fixed target of mean blood pressure around 65 mmHg should be obtained) using these medications in the following order fentanyl 0.5 ug/kg.
Degree of pain 24 hours postoperatively Each patient will be instructed about postoperative pain assessment with the visual analogue scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS: will be assessed at 0, 4, 8, 12, and 24 h postoperatively
Time to extubation One hour postoperatively Time to extubation: the time from discontinuing anesthesia to fulfilling extubation criteria will be recorded.
Recovery time One hour postoperatively Recovery time: the time from extubation, till patients attain an Aldrete score \>9, will be recorded.
Heart rate 135 min post-procedure Heart rate will be recorded after induction of general anesthesia, at the entrance of the endoscope, after 15, 30, 45, 60, 75, 90, 105, 120, and 135 min.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Tanta University
🇪🇬Tanta, El-Gharbia, Egypt
Tanta University🇪🇬Tanta, El-Gharbia, EgyptMostafa I Sharaf, MDContact00201009470868mostafa.sharaf@med.tanta.edu.egAhmed S Abdelhamid, MDPrincipal InvestigatorKhaled Hamama, MDPrincipal Investigator